Psychiatry News

ATLANTA — Younger women with a diagnosis of anxiety or depression are at markedly higher risk for developing conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes, researchers reported.

Artificial intelligence language models were able to accurately predict the severity of depression symptoms based on social media posts among white people but not among Black people, according to a recent study.

According to results published in Orthopedics, patients with vs. without psychiatric diagnoses, such as depression, bipolar disorder, anxiety disorder and schizophrenia, had similar clinical outcomes after fracture-related infection.

The long-term adjudicated suicidal ideation and behavior rate in patients with psoriasis treated with bimekizumab was low and within general psoriasis population ranges, according to a study.

The risk for mental health conditions and self-harm or suicide was higher among partners and adult offspring of stroke survivors vs. the general population and family of myocardial infarction survivors, according to a study in Denmark.

A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and development of allosteric modulator therapeutics to address underserved neurological disorders.

Suicide is now the second most common cause of death among college athletes in the United States, surpassed only by accidents, according to findings published in the British Journal of Sports Medicine.

Women are not universally at risk for depressive symptoms during menopause transition, but providers should be aware of risk factors and treat mental health disorders promptly, according to a review published in The Lancet.

The presence of a sleep disorder was associated with increased health care use in youth with chronic medical conditions, a study in the Journal of Clinical Sleep Medicine showed.

Neurocrine Biosciences Inc. announced a phase 1 study to evaluate an investigational neuropsychiatric therapy in healthy adults, as well as commencement of dosing in a phase 2 study of a novel oral compound for major depressive disorder.